An Update on the Safety and Tolerability of Pimecrolimus Cream 1%: Evidence from Clinical Trials and Post-Marketing Surveillance
The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Abstract
In this report, we review the data on the safety and tolerability of pimecrolimus cream 1% (Elidel®) from clinical trials and post-marketing surveillance in patients with atopic dermatitis. These data demonstrate that topically applied pimecrolimus is minimally absorbed through the skin and has afavourable safety margin. The most common treatment-related adverse events are transient local reactions, particularly skin burning (16.1 and 12.9 events per 1,000 patient-months of follow-up in adults and children, respectively). When compared to the vehicle, the use of pimecrolimus cream 1% is associated with an increased incidence of herpes simplex virus infections in children (relative risk: 2.5; 95% confidence interval: 1.2–5.8; p = 0.017). However, pimecrolimus cream 1% does not increase the incidence of any skin infection in comparison with moderately potent topical corticosteroids and lacks other corticosteroid-related side effects such as skin atrophy. While cases of malignancy have been reported in patients who have used pimecrolimus cream 1%, there is no clinical evidence to establish that treatment with pimecrolimus cream 1% increases the risk of malignancy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
TURPEINEN, M., SALO, O. P., & LEISTI, S. (1986) · British Journal of Dermatology · doi:10.1111/j.1365-2133.1986.tb06242.x · Cited by 104
Enhanced DDB2 expression protects mice from carcinogenic effects of chronic UV-B irradiation
Alekseev, S., Kool, H., Rebel, H., Fousteri, M., Moser, J., Backendorf, C., de Gruijl, F. R., Vrieling, H., & Mullenders, L. H. F. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-2295 · Cited by 77 · cited 1×
“The relevance of this finding to humans is doubtful because, unlike human cells, rodent epidermal cells are deficient in the global genome repair of UV-induced cyclobutane pyrimidine dimers [”
Background
Cited by
Evidence‐based (S3) Guideline on (anogenital) Lichen sclerosus
Kirtschig, G., Becker, K., Günthert, A., Jasaitiene, D., Cooper, S., Chi, C. ‐., Kreuter, A., Rall, K. K., Aberer, W., Riechardt, S., et al. (2015) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.13136 · Cited by 350
Siegfried, E. C., Jaworski, J. C., Kaiser, J. D., & Hebert, A. A. (2016) · BMC Pediatrics · doi:10.1186/s12887-016-0607-9 · Cited by 194
Therapeutic implications of a barrier-based pathogenesis of atopic dermatitis
Elias, P. M., & Wakefield, J. S. (2011) · Clinical Reviews in Allergy & Immunology · doi:10.1007/s12016-010-8231-1 · Cited by 103
Bissonnette, R., Poulin, Y., Zhou, Y., Tan, J., Hong, H. C., Webster, J., Ip, W., Tang, L., & Lyle, M. (2012) · British Journal of Dermatology · doi:10.1111/j.1365-2133.2011.10775.x · Cited by 92
Metadata
- Authors
- Langley, R. G. B., Luger, T. A., Cork, M. J., Schneider, D., & Paul, C.
- Venue
- Dermatology
- Publisher
- S. Karger AG
- Published
- 2007
- Volume
- 215
- Issue
- Suppl. 1
- Pages
- 27-44
- ISSN
- 1018-8665 (ISSN-L)
- 1421-9832
- OpenAlex
- W2039981985
- Cited by
- 40
- References
- 2
- FWCI
- 6.20
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: An Update on the Safety and Tolerability of Pimecrolimus Cream 1%: Evidence from Clinical Trials and Post-Marketing Surveillance. https://app.cochat.ai/papers/10.1159/000102118
- The paper
- Langley, R. G. B., Luger, T. A., Cork, M. J., Schneider, D., & Paul, C. (2007). An Update on the Safety and Tolerability of Pimecrolimus Cream 1%: Evidence from Clinical Trials and Post-Marketing Surveillance. Dermatology. https://doi.org/10.1159/000102118
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.